Bacterial Hijacking of Host Mitophagy: Mechanisms Uncovered in B. pseudomallei Infection

Study Background and Research Question

Mitochondrial quality control is central to cellular homeostasis, with mitophagy serving as a key pathway for removing damaged mitochondria and regulating oxidative stress. Pathogens have evolved diverse strategies to manipulate host mitophagy, thereby evading immune responses and promoting intracellular persistence. Burkholderia pseudomallei, the causative agent of melioidosis, is an intracellular bacterium notorious for its capacity to persist and evade host immunity. While prior studies have implicated mitophagy in the pathogenesis of viral and bacterial infections, the specific molecular mechanisms by which B. pseudomallei modulates host mitophagy remained unclear. The central question addressed by the paper is: How does B. pseudomallei exploit host ubiquitin ligase complexes to manipulate mitophagy?

Key Innovation from the Reference Study

The principal innovation of the study lies in the discovery that B. pseudomallei’s type III secretion system needle tip protein, BipD, directly interacts with the host’s KLHL9 and KLHL13 proteins, which are BTB (Broad-Complex, Tramtrack and Bric a brac) domain-containing adaptors for the cullin-RING ligase 3 (CRL3) complex. This interaction facilitates the recruitment of CUL3, a NEDD8 family E3 ligase, to mitochondria, leading to targeted ubiquitination of the inner mitochondrial membrane protein IMMT (also known as mitofilin). Notably, this mechanism operates independently of canonical mitophagy regulators like Parkin, representing a previously uncharacterized bacterial strategy for modulating host mitochondrial turnover (reference study).

Methods and Experimental Design Insights

The authors employed a multidisciplinary approach combining molecular biology, proteomics, and infection models. Key experimental strategies included:

• Use of mouse macrophage cell lines infected with B. pseudomallei to monitor mitophagy induction.
• Immunoprecipitation and mass spectrometry to map BipD-host protein interactions and identify interacting E3 ligase components.
• CRISPR/Cas9-mediated gene editing and siRNA knockdowns to dissect the roles of KLHL9, KLHL13, CUL3, and IMMT in the mitophagy pathway.
• Ubiquitome profiling to identify IMMT as a substrate of CRL3 and to pinpoint the specific lysine (K211) subject to K63-linked ubiquitination.
• Rescue and complementation assays to confirm the requirement for IMMT K211 ubiquitination in mitophagy induction and suppression of mitochondrial ROS.

Core Findings and Why They Matter

The study demonstrates that BipD binds to the Back and Kelch domains of KLHL9 and KLHL13, promoting assembly of the CRL3 E3 ligase complex at the mitochondria. This, in turn, leads to K63-linked ubiquitination of IMMT at lysine 211, a modification shown to be critical for the initiation of mitophagy. Disruption of this pathway, either by knocking down KLHL9/KLHL13/CUL3 or by mutating IMMT K211, abrogates mitophagy and increases mitochondrial ROS, ultimately reducing bacterial survival within host cells (reference study).

This mechanism is significant for several reasons:

• It uncovers a non-canonical mitophagy pathway, independent of the well-studied PINK1/Parkin axis, that is specifically hijacked by B. pseudomallei.
• It identifies IMMT as a critical node in host-pathogen interactions and positions the CRL3 complex as a potential therapeutic target.
• It reveals how bacterial virulence factors can exploit the neddylation pathway and cullin-RING ligase-mediated ubiquitination to subvert innate immune defenses.

Comparison with Existing Internal Articles

Several internal resources provide context for the molecular tools used to dissect pathways like those illuminated in this study. For example, guidance on MLN4924 (SKU B1036) details how selective NEDD8-activating enzyme inhibition enables precise interrogation of neddylation-dependent E3 ligase activity, including CRL complexes. The referenced paper’s focus on CRL3-mediated ubiquitination of IMMT aligns with workflows described in translational cancer models, where MLN4924 is used to study CRL-dependent ubiquitination, cell cycle regulation, and substrate stabilization. These internal articles emphasize the value of selective NAE inhibitors in both oncology and infection biology, highlighting their capacity to dissect cullin-RING ligase (CRL) ubiquitination inhibition and neddylation pathway inhibition with high specificity.

Limitations and Transferability

While the study provides compelling evidence for the BipD–CRL3–IMMT axis in murine macrophages, several limitations must be considered:

• Most experiments were performed in mouse-derived cells and may not fully recapitulate human host-pathogen interactions.
• The broader applicability of this mechanism to other intracellular pathogens or cell types remains to be determined.
• Therapeutic targeting of neddylation and CRL3 activity must be approached with caution, given the essential roles of these pathways in cellular homeostasis and the risk of off-target effects.

Why this cross-domain matters, maturity, and limitations

The elucidation of a bacterial strategy that converges on host neddylation and CRL3 activity underscores the intersection between infection biology and cancer research. Both domains leverage the modulation of ubiquitin-proteasome system components, suggesting that tools developed for cancer biology—such as selective NEDD8-activating enzyme inhibitors—can be repurposed for infection models. However, direct clinical translation is still at an early stage, and further studies in primary human cells and in vivo infection models are needed to validate these findings and assess therapeutic windows.

Protocol Parameters

• CRISPR/Cas9 knockout or siRNA knockdown: Target KLHL9, KLHL13, CUL3, or IMMT to establish pathway dependency in mitophagy induction.
• MLN4924 (NEDD8-activating enzyme inhibitor) treatment: Use at concentrations validated for robust neddylation pathway inhibition (typical in vitro range: 0.1–1 μM; refer to product documentation for solubility and dosing).
• Ubiquitome profiling: Employ immunoprecipitation with anti-K63 ubiquitin antibodies followed by mass spectrometry to identify substrate modifications.
• Mitophagy assessment: Evaluate LC3-II accumulation, mitochondrial clearance, and ROS production using confocal microscopy, flow cytometry, and ROS-specific dyes.

Research Support Resources

For researchers aiming to explore neddylation pathway inhibition or dissect CRL3-dependent ubiquitination in infection or cancer models, MLN4924 (SKU B1036) is a potent and selective NEDD8-activating enzyme inhibitor suitable for in vitro and in vivo studies. Its robust selectivity profile and well-characterized solubility in DMSO facilitate reproducible investigation of cullin-RING ligase function and neddylation-dependent processes. For in-depth cancer biology research and advanced protocol optimization, additional practical insights can be found in specialized articles such as those hosted by APExBIO and internal research platforms.